S-allylmercaptocysteine | 2281-22-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: S-allylmercaptocysteine
• 英文别名: S-(Allylthio)-L-cysteine；2-amino-3-(prop-2-enyldisulfanyl)propanoic acid
• CAS: 2281-22-3
• 化学式: C₆H₁₁NO₂S₂
• 分子量: 193.291
• InChiKey: WYQZZUUUOXNSCS-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid
• 熔点：
  187-188°C

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  5

制备方法与用途

S-烯丙基巯基半胱氨酸是一种从大蒜中提取的有机硫化合物，具有抗炎和抗氧化作用，尤其对各种肺部疾病有益。该物质通过多种途径实现抗癌效果，例如通过诱导癌细胞凋亡来抑制TGF-β信号通路，或者降低NF-κB活性并上调Nrf2，从而达到抗炎和抗氧化的目的[1][2][3]。

反应信息

• 作为产物：
  描述：

  DL-半胱氨酸 、 (E)-ajoene 生成 S-allylmercaptocysteine
  参考文献：
  名称：

  [EN] INTEGRIN MODULATORS AND METHODS FOR THEIR USE
  [FR] MODULATEURS D'INTEGRINE ET METHODES D'UTILISATION DE CES MODULATEURS

  摘要：

  描述了1,5-二硫杂辛二烯-5-氧化-1-基(DODOyl)化合物及其衍生物，统称为DODOyl衍生化合物(DDCs)，以及手性对映体和其衍生物，它们是调节整合素介导功能和/或过程的整合素调节剂。进一步描述了含有整合素调节剂和手性对映体的药物组合物，以及使用整合素调节剂和手性对映体的方法。

  公开号：

  WO2005087717A1

文献信息

• USE OF ALLYLCYSTEINE OR ITS ANALOGS AND PHARMACEUTICAL COMPOSITION THREROF
  申请人：Fudan University

  公开号：EP2186512A1

  公开（公告）日：2010-05-19

  The invention discloses a use of compound S-allyl cysteine or its analogues in preparation of medicaments for preventing or treating myocardial injury and a preparation method thereof, as well as a pharmaceutical composition comprising the compound.

  该发明揭示了利用复合S-烯丙基半胱氨酸或其类似物制备用于预防或治疗心肌损伤的药物以及其制备方法，以及包含该化合物的药物组合物。
• Method Of Synthesizing S-Allyl-Cysteine Analogues And Their Therapeutic Application In Treating Myocardial Infarction
  申请人：ZHU YIZHUN

  公开号：US20090036534A1

  公开（公告）日：2009-02-05

  A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier.

  揭示了一种用于治疗受试者心肌梗死的药物组合物及其制备和应用方法。该药物组合物包括从SEC、SPC、SBC、SPEC、SAC、SAMC和SPRC等化合物组合中选择的至少一种合成化合物的治疗有效量，以及一种药用可接受的载体。
• AGENT FOR PREVENTING, AMELIORATING, OR TREATING PERIODONTAL DISEASE
  申请人：Wakunaga Pharmaceutical Co., Ltd.

  公开号：EP3970793A1

  公开（公告）日：2022-03-23

  Provided is a medicine or food useful for preventing, ameliorating or treating periodontal disease. An agent for preventing, ameliorating or treating periodontal disease comprises one or more cysteine derivatives selected from the group consisting of S1PC, SAC and SAMC or a salt thereof as an active ingredient.

  本发明提供了一种用于预防、改善或治疗牙周病的药物或食品。一种用于预防、改善或治疗牙周病的制剂包含一种或多种选自 S1PC、SAC 和 SAMC 所组成的组的半胱氨酸衍生物或其盐作为活性成分。
• Novel protein: prenyl transferase inhibitors
  申请人：NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO

  公开号：EP1028117B1

  公开（公告）日：2002-06-12
• Method to increase the bioavailability of cysteine
  申请人：Ott M. David

  公开号：US20070275876A1

  公开（公告）日：2007-11-29

  A method for increasing the bioavailability of cysteine within an animal by reducing extracellular cysteine disulfide molecules to produce extracellular cysteine molecules. A membrane permeable thiol molecule that forms a membrane permeable disulfide molecule after becoming oxidized participates in thiol-disulfide exchange reactions on both sides of the cellular membrane, crossing the membrane randomly via simple diffusion. The membrane permeable disulfide, within or upon entering the highly reductive environment of a cell, becomes reduced to form a membrane permeable thiol molecule. the membrane permeable thiol can then diffuse to the exterior of the cell, where it is available to reduce another cystine molecule. This process can continue cycling, producing net cumulative increase in the concentration of extracellular cysteine. This is beneficial for providing cysteine as a nutrient to cells that require cysteine for nourishment.